AstraZeneca has reported positive “high-level” outcomes from the randomised Phase III MATTERHORN trial of Imfinzi (durvalumab ...

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...

Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...

(Sharecast News) - AstraZeneca said its Imfinzi drug when used with chemotherapy had shown "statistically significant and clinically meaningful improvement" in survival in resectable early-stage ...

AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities ...

AstraZeneca's lengthy and turbulent development ... by the FDA in the US for use in tandem with AZ's PD-L1 inhibitor Imfinzi (durvalumab) to treat adults with unresectable hepatocellular carcinoma ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

After a long run of trial disappointments, AstraZeneca is celebrating a win for its immuno-oncology combination of Imfinzi plus tremelimumab in advanced liver cancer. The mid-stage Study 22 trial ...